Cost Saving Opportunities in NSCLC Therapy by Optimized Diagnostics
Abstract
:1. Introduction
2. Results
3. Discussion
4. Materials and Methods
5. Conclusions
Acknowledgments
Author Contributions
Conflicts of Interest
References
- Li, T.; Maus, M.K.; Desai, S.J.; Beckett, L.A.; Stephens, C.; Huang, E.; Hsiang, J.; Zeger, G.; Danenberg, K.D.; Astrow, S.H.; et al. Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays. J. Thorac. Oncol. 2014, 9, 18–25. [Google Scholar] [CrossRef] [PubMed]
- Maus, M.K.; Stephens, C.; Zeger, G.; Grimminger, P.P.; Huang, E. Identification of novel variant of EML4-ALK fusion gene in NSCLC: Potential benefits of the RT-PCR method. Int. J. Biomed. Sci. 2012, 8, 1–6. [Google Scholar] [PubMed]
- To, K.F.; Tong, J.H.; Yeung, K.S.; Lung, R.W.; Law, P.P.; Chau, S.L.; Kang, W.; Tong, C.Y.; Chow, C.; Chan, A.W.; et al. Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant. J. Thorac. Oncol. 2013, 8, 883–891. [Google Scholar] [CrossRef] [PubMed]
- Olsen, D.; Jorgensen, J.T. Companion diagnostics for targeted cancer drugs—Clinical and regulatory aspects. Front. Oncol. 2014, 4, 105. [Google Scholar] [CrossRef] [PubMed]
- Mak, K.S.; Gainor, J.F.; Niemierko, A.; Oh, K.S.; Willers, H.; Choi, N.C.; Loeffler, J.S.; Sequist, L.V.; Shaw, A.T.; Shih, H.A. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases. Neuro Oncol. 2015, 17, 296–302. [Google Scholar] [CrossRef] [PubMed]
- Kasapoglu, U.S.; Arinc, S.; Gungor, S.; Irmak, I.; Guney, P.; Aksoy, F.; Bandak, D.; Hazar, A. Prognostic factors affecting survival in non-small cell lung carcinoma patients with malignant pleural effusions. Clin. Respir. J. 2015, 10, 791–799. [Google Scholar] [CrossRef] [PubMed]
- Barlesi, F.; Mazieres, J.; Merlio, J.P.; Debieuvre, D.; Mosser, J.; Lena, H.; Ouafik, L.; Besse, B.; Rouquette, I.; Westeel, V.; et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: Results of a 1-year nationwide programme of the french cooperative thoracic intergroup (IFCT). Lancet 2016, 387, 1415–1426. [Google Scholar] [CrossRef]
- Pan, Y.; Zhang, Y.; Li, Y.; Hu, H.; Wang, L.; Li, H.; Wang, R.; Ye, T.; Luo, X.; Zhang, Y.; et al. Alk, ros1 and ret fusions in 1139 lung adenocarcinomas: A comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. Lung Cancer 2014, 84, 121–126. [Google Scholar] [CrossRef] [PubMed]
- Zhao, N.; Zheng, S.Y.; Yang, J.J.; Zhang, X.C.; Xie, Z.; Xie, B.; Su, J.; Chen, Z.H.; Chen, S.L.; Zhang, N.; et al. Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: A case report and literature review. Clin. Lung Cancer 2015, 16, e5–e9. [Google Scholar] [CrossRef] [PubMed]
- Mano, H. The EML4-ALK oncogene: Targeting an essential growth driver in human cancer. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 2015, 91, 193–201. [Google Scholar] [CrossRef] [PubMed]
- Lozano, M.D.; Labiano, T.; Zudaire, I.; Subtil, J.C.; Gurpide, A.; Echeveste, J.I.; Zulueta, J.J.; Martin-Algarra, S.; Perez-Gracia, J.L. Variations in molecular profile in NSCLC can be analyzed using cytological samples: Development of EGFR resistance mutations and coexistence of ALK-EML4 translocation in an EGFR-sensitive patient. Int. J. Surg. Pathol. 2015, 23, 111–115. [Google Scholar] [CrossRef] [PubMed]
- Liu, L.; Zhan, P.; Zhou, X.; Song, Y.; Yu, L.; Wang, J. Detection of EML4-ALK in lung adenocarcinoma using pleural effusion with fish, IHC, and RT-PCR methods. PLoS ONE 2015, 10, e0117032. [Google Scholar] [CrossRef] [PubMed]
- Li, W.; Qu, J.; Xu, Z. Clinical features and mutation status of EGFR, KRAS, BRAF, EML4-ALK and ros1 between surgical resection samples and non surgical resection samples in lung cancer. J. Thorac. Dis. 2015, 7, 875–880. [Google Scholar] [PubMed]
- Guerin, A.; Sasane, M.; Wakelee, H.; Zhang, J.; Culver, K.; Dea, K.; Nitulescu, R.; Galebach, P.; Macalalad, A.R. Treatment, overall survival, and costs in patients with ALK-positive non-small-cell lung cancer after crizotinib monotherapy. Curr. Med. Res. Opin. 2015, 31, 1587–1597. [Google Scholar] [CrossRef] [PubMed]
- Kousoulakou, H.; Boukovinas, I.; Georgoulias, V.; Kosmidis, P.; Koumakis, G.; Makrantonakis, P.; Samantas, E.; Syrigos, K.; Krikelis, D.; Markouri, A.; et al. The management and costs of locally advanced or metastatic ALK-positive non-small cell lung cancer in greece. Value Health 2015, 18, A451. [Google Scholar] [CrossRef] [PubMed]
- Shaw, A.T.; Yeap, B.Y.; Mino-Kenudson, M.; Digumarthy, S.R.; Costa, D.B.; Heist, R.S.; Solomon, B.; Stubbs, H.; Admane, S.; McDermott, U.; et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 2009, 27, 4247–4253. [Google Scholar] [CrossRef] [PubMed]
- Kwak, E.L.; Bang, Y.J.; Camidge, D.R.; Shaw, A.T.; Solomon, B.; Maki, R.G.; Ou, S.H.; Dezube, B.J.; Janne, P.A.; Costa, D.B.; et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 2010, 363, 1693–1703. [Google Scholar] [CrossRef] [PubMed]
- Ou, S.H.; Bazhenova, L.; Camidge, D.R.; Solomon, B.J.; Herman, J.; Kain, T.; Bang, Y.J.; Kwak, E.L.; Shaw, A.T.; Salgia, R.; et al. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, pf02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J. Thorac. Oncol. 2010, 5, 2044–2046. [Google Scholar] [CrossRef] [PubMed]
- Shaw, A.T.; Yeap, B.Y.; Solomon, B.J.; Riely, G.J.; Gainor, J.; Engelman, J.A.; Shapiro, G.I.; Costa, D.B.; Ou, S.H.; Butaney, M.; et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis. Lancet Oncol. 2011, 12, 1004–1012. [Google Scholar] [CrossRef]
- Lunge. Available online: http://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2015/kid_2015_c33_c34_lunge.pdf?__blob=publicationFile (accessed on 15 June 2017).
- Hammerschmidt, S.; Wirtz, H. Lung cancer: Current diagnosis and treatment. Dtsch. Arztebl. Int. 2009, 106, 809–818. [Google Scholar] [PubMed]
- Von Laffert, M.; Warth, A.; Penzel, R.; Schirmacher, P.; Jonigk, D.; Kreipe, H.; Schildhaus, H.U.; Merkelbach-Bruse, S.; Buttner, R.; Reu, S.; et al. Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): Results of a multi-centre ALK-testing. Lung Cancer 2013, 81, 200–206. [Google Scholar]
- Von Laffert, M.; Penzel, R.; Schirmacher, P.; Warth, A.; Lenze, D.; Hummel, M.; Dietel, M. Multicenter ALK testing in non-small-cell lung cancer: Results of a round robin test. J. Thorac. Oncol. 2014, 9, 1464–1469. [Google Scholar] [CrossRef] [PubMed]
- Wolf, J. Personalized, targeted treatment of non-small cell lung cancer. Dtsch. Med. Wochenschr. 2011, 136, 480–485. [Google Scholar] [CrossRef] [PubMed]
- Kelly, R.J.; Hillner, B.E.; Smith, T.J. Cost effectiveness of crizotinib for anaplastic lymphoma kinase-positive, non-small-cell lung cancer: Who is going to blink at the cost? J. Clin. Oncol. 2014, 32, 983–985. [Google Scholar] [CrossRef] [PubMed]
- Yousem, S.A. Role of molecular studies in the diagnosis of lung adenocarcinoma. Mod. Pathol. 2012, 25 (Suppl. 1), S11–S17. [Google Scholar] [CrossRef] [PubMed]
- Warth, A.; Stenzinger, A.; Weichert, W. Novel morphological and molecular aspects of lung cancer. Pathologe 2013, 34, 419–428. [Google Scholar] [CrossRef] [PubMed]
- Köhler, J.; Schuler, M. Personalisierte medikamentöse therapie des fortgeschrittenen nicht-kleinzelligen lungenkarzinoms. Onkologe 2011, 17, 702–708. [Google Scholar] [CrossRef]
- Deutsche Internet Apotheke. Available online: https://www.deutscheinternetapotheke.de/xalkori-250-mg-hartkapseln/09884710 (accessed on 24 March 2016).
- Popper, H.H.; Ryska, A.; Timar, J.; Olszewski, W. Molecular testing in lung cancer in the era of precision medicine. Transl. Lung Cancer Res. 2014, 3, 291–300. [Google Scholar] [PubMed]
- Statistiken zur Bevölkerung und zum Bevölkerungswachstum. Available online: http://ec.europa.eu/eurostat/statistics-explained/index.php/Population_and_population_change_statistics/de (accessed on 15 June 2017).
- Lengauer, T.; Sing, T. Bioinformatics-assisted anti-HIV therapy. Nat. Rev. Microbiol. 2006, 4, 790–797. [Google Scholar] [CrossRef] [PubMed]
- Thielen, A.; Lengauer, T. Geno2pheno (454): A web server for the prediction of HIV-1 coreceptor usage from next-generation sequencing data. Intervirology 2012, 55, 113–117. [Google Scholar] [CrossRef] [PubMed]
- Lengauer, T.; Sander, O.; Sierra, S.; Thielen, A.; Kaiser, R. Bioinformatics prediction of HIV coreceptor usage. Nat. Biotechnol. 2007, 25, 1407–1410. [Google Scholar] [CrossRef] [PubMed]
- Bozek, K.; Eckhardt, M.; Sierra, S.; Anders, M.; Kaiser, R.; Krausslich, H.G.; Muller, B.; Lengauer, T. An expanded model of HIV cell entry phenotype based on multi-parameter single-cell data. Retrovirology 2012, 9, 60. [Google Scholar] [CrossRef] [PubMed]
- Bogojeska, J.; Lengauer, T. Hierarchical bayes model for predicting effectiveness of HIV combination therapies. Stat. Appl. Genet. Mol. Biol. 2012, 11, 11. [Google Scholar] [CrossRef]
- Pfeifer, N.; Lengauer, T. Improving HIV coreceptor usage prediction in the clinic using hints from next-generation sequencing data. Bioinformatics 2012, 28, i589–i595. [Google Scholar] [CrossRef] [PubMed]
- Schildgen, V.; Schildgen, O. Routine molecular profiling of patients with NSCLC. Lancet 2016, 388, 1054. [Google Scholar] [CrossRef]
- Jurgens, J.; Engel-Riedel, W.; Stoelben, E.; Schildgen, V.; Schildgen, O.; Brockmann, M. The (con-) fusion in ALK diagnostics: When food and drug administration-approved algorithms fail. J. Clin. Oncol. 2016, 34, 1961–1962. [Google Scholar] [CrossRef] [PubMed]
- Jurgens, J.; Engel-Riedel, W.; Prickartz, A.; Ludwig, C.; Schildgen, O.; Tillmann, R.L.; Stoelben, E.; Brockmann, M.; Schildgen, V. Combined point mutation in KRAS or EGFR genes and EML4-ALK translocation in lung cancer patients. Future Oncol. 2014, 10, 529–532. [Google Scholar] [CrossRef] [PubMed]
- Schildgen, V.; Lüsebrink, J.; Schildgen, O.; Stoelben, E.; Brockmann, M. Epidemiology of KRAS, BRAF, and EGFR mutations in lung cancer in a german tertiary hospital in patients with testing indication. Pers. Med. 2016, 315–323. [Google Scholar] [CrossRef]
- Loens, K.; van Loon, A.M.; Coenjaerts, F.; van Aarle, Y.; Goossens, H.; Wallace, P.; Claas, E.J.; Ieven, M.; Group, G.S. Performance of different mono- and multiplex nucleic acid amplification tests on a multipathogen external quality assessment panel. J. Clin. Microbiol. 2012, 50, 977–987. [Google Scholar] [CrossRef] [PubMed]
- Reijans, M.; Dingemans, G.; Klaassen, C.H.; Meis, J.F.; Keijdener, J.; Mulders, B.; Eadie, K.; van Leeuwen, W.; van Belkum, A.; Horrevorts, A.M.; et al. Respifinder: A new multiparameter test to differentially identify fifteen respiratory viruses. J. Clin. Microbiol. 2008, 46, 1232–1240. [Google Scholar] [CrossRef] [PubMed]
Patient No. | Age at Therapy Start (Years) | Sex | Smoking Status | Length of Crizotinib Therapy (Month) | Exitus Letalis Post Therapy (Month) |
---|---|---|---|---|---|
1 | 75 | female | ex-smoker | 1 | |
2 | 69 | female | never-smoker | 15 | 28 |
3 | 75 | male | ex-smoker | 2 | 2 |
4 | 50 | female | ex-smoker | 15 | 15 |
5 | 74 | male | ex-smoker | 4 | |
6 | 62 | male | smoker | 9 | |
7 | 73 | male | smoker | 1 | 1 |
8 | 76 | female | ex-smoker | 25, ongoing | |
9 | 65 | male | ex-smoker | 2 | |
10 | 48 | male | ex-smoker | 1 | |
11 | 63 | male | smoker | 2 | 3 |
12 | 56 | male | ex-smoker | 1 | 1 |
13 | 53 | female | smoker | 4 | |
14 | 55 | male | never-smoker | 1, ongoing | |
15 | 48 | female | ex-smoker | 1 | 2 |
16 | 62 | female | ex-smoker | 2 | |
17 | 65 | female | smoker | 2 | |
18 | 71 | male | ex-smoker | 2 | 2 |
19 | 54 | male | unknown | 15 | |
20 | 51 | male | never-smoker | 4 | |
21 | 55 | male | smoker | 1 | 1 |
22 | 79 | male | ex-smoker | 8, ongoing | |
mean: 62.68 years | average therapy duration: 5.36 months | ||||
median: 62.5 years | median therapy duration: 2 months |
Clinical and Therapy Information | Our Hospital | Germany | European Union |
---|---|---|---|
patients with lung carcinoma | 645 (in 2014) * | 55,300 (2016) | 411,765 (extrapolated) |
patients with NSCLC | 574 (in 2014) * | 47,005 (85%) | 350,000 (85%) |
number of ALK positive patients eligible for ALK therapy ≥1 month | 20 (per year from 2012–2015) | 470–940 (1%–2% of NSCLC) | 3500–7000 (1%–2% of NSCLC) |
number of ALK positive patients treated per year | 7.33 | 172–355 ** | 1283–2566 ** |
average duration of ALK-inhibitor therapy | 5.36 months | ||
median duration of ALK-inhibitor therapy | 2 months | ||
total cumulated average therapy duration per year | 39.29 months | 921.92 months–1902.8 months ** | 6877.1 months–13,754.2 months ** |
total cumulated median therapy duration per year | 14.66 months | 344–710 months ** | 2566–5132 months ** |
total costs per year based on average therapy duration | 239,181.18 € | 5,612,436.92 €–11,583,808.76 € ** | 41,864,864.11 €–83,729,728.22 € *** |
total costs per year based on median therapy duration | 89,246.71 € | 2,094,192.88 €–4,322,316.70 € ** | 15,621,218.14 €–31,242,436.27 € ** |
Kliniken der Stadt Köln gGmbH | Germany | European Union | |
---|---|---|---|
number of ALK-positive patients with ALK-inhibitor therapy per year | 7.33 | 172–355 | 1283–2566 |
non-responders | 72.73% | ||
cost-saving potential based on average therapy duration of non-responders | 62,880.72 € | 1,475,509.41 €–3,045,382.78 € | 11,006,270.64 €–22,012,541.27 € |
cost-saving potential based on median therapy duration of non-responders | 64,909.13 € | 1,523,106.48 €–3,143,620.94 € | 11,361,311.57 €–22,722,623.14 € |
average cost-saving potential calculated on our cohort | 219,096.56 € | 5,141,147.77 € | 38,349,370.60 € |
median cost-saving potential calculated on our cohort | 226,164.22 € | 5,306,991.22 € | 39,586,452.15 € |
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Nenadić, I.; Staber, J.; Dreier, S.; Simons, G.; Schildgen, V.; Brockmann, M.; Schildgen, O. Cost Saving Opportunities in NSCLC Therapy by Optimized Diagnostics. Cancers 2017, 9, 88. https://doi.org/10.3390/cancers9070088
Nenadić I, Staber J, Dreier S, Simons G, Schildgen V, Brockmann M, Schildgen O. Cost Saving Opportunities in NSCLC Therapy by Optimized Diagnostics. Cancers. 2017; 9(7):88. https://doi.org/10.3390/cancers9070088
Chicago/Turabian StyleNenadić, Ilija, Janine Staber, Susanne Dreier, Guus Simons, Verena Schildgen, Michael Brockmann, and Oliver Schildgen. 2017. "Cost Saving Opportunities in NSCLC Therapy by Optimized Diagnostics" Cancers 9, no. 7: 88. https://doi.org/10.3390/cancers9070088